1.35, 2.06, 35 trials and 6769 patients) was observed in patients treated with recombinant human erythropoietin.
1, 35, 2, 06, 35 uuringut ja 6769 patsienti) täheldati patsientidel, keda raviti inimese rekombinantse erütropoetiiniga.